Alvotech adds US capacity with LOTTE Biologics
Also: BridgeBio priority review, a rival to Ascendis; Lundbeck Parkinson’s data; Forbion’s €2.3bn funds; Alzinova rights issue.
Alvotech adds US capacity with LOTTE Biologics Beitrag lesen »
Genmab’s epcoritamab succeeds in frontline DLBCL
Also: Alvotech’s FDA capacity win, CSL–Alentis deal worth up to $1.6bn, new Idorsia data at AHA.
Genmab’s epcoritamab succeeds in frontline DLBCL Beitrag lesen »